To Evalaute the Efficacy of Metformin Monotherapy in Newly Diagnosed Type 2 Diabetes Mellitus Patients by Assesing the HBA1C Percentage Reduction as a Single Diagnostic Tool for Glycemic Control and its Incidence in Preventing Macrovascular Complications: A Prospective Open Label Study for a Period of 6 Months Duration